ABT-450/ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus

Bibliography

• Gower E, Estes C C, Hindman S, et al. Global epidemiology and genotype distribution of the hepatitis C virus. J Hepatol 2014;61(1 Suppl):S45-57
   PubMed Web of Science ®Google Scholar
• Gravitz L. Introduction: a Smouldering Public-Health Crisis. Nature 2011;474(7350):S2-4
   PubMed Web of Science ®Google Scholar
• Kabiri M, Jazwinski AB, Roberts MS, et al. The changing burden of hepatitis C virus infection in the United States: model-based predictions. Ann Intern Med 2014;161(3):170-80
   PubMed Web of Science ®Google Scholar
• Alter MJ, Margolis HS, Bell BP, et al. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Morb Mortal Wkly Rep 1998;47(1):1-39
   PubMedGoogle Scholar
• Davis GL, Alter MJ, El–Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010;138(2):513-21; e6
   PubMed Web of Science ®Google Scholar
• Razavi H, Waked I, Sarrazin C, et al. The present and future disease burden of hepatitis C virus (HCV) infection with today’s treatment paradigm. J Viral Hepat 2014;21(s1):34-59
   PubMedGoogle Scholar
• Deuffic–Burban S, Deltenre P, Buti M, et al. Predicted effects of treatment for HCV infection vary among European countries. Gastroenterology 2012;143(4):974-85; e14
   PubMedGoogle Scholar
• Sypsa V, Touloumi G, Tassopoulos N, et al. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection. J Viral Hepat 2004;11(4):366-74
   PubMedGoogle Scholar
• Carney K, Dhalla S, Aytaman A, et al. Association of tattooing and hepatitis C virus infection: A multicenter case-control study. Hepatology 2013;57(6):2117-23
   PubMed Web of Science ®Google Scholar
• Vermehren J, Sarrazin C. New HCV therapies on the horizon. Clin Microbiol Infect 2011;17(2):122-34
   PubMedGoogle Scholar
• Wedemeyer H, Duberg A, Buti M, et al. Strategies to manage hepatitis C virus (HCV) disease burden. J Viral Hepat 2014;21(s1):60-89
   PubMedGoogle Scholar
• Martin NK, Hickman M, Hutchinson SJ, et al. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy. Clin Infect Dis 2013;57(Suppl 2):S39-45
   PubMedGoogle Scholar
• Burman BE, Kwo PY, Kowdley KV. Comparison of first-and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity. Hepatol Int 2014;8(3):352-64
   PubMedGoogle Scholar
• Carrion AF, Gutierrez J, Martin P. New antiviral agents for the treatment of hepatitis C: ABT-450. Expert Opin Pharmacother 2014;15(5):711-16
   PubMed Web of Science ®Google Scholar
• Gallay PA, Lin K. Profile of alisporivir and its potential in the treatment of hepatitis C. Drug Des Devel Ther 2013;7:105
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Hézode C, Zeuzem S, Pawlotsky J. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012;56:S88-S100
   PubMed Web of Science ®Google Scholar
• Stedman CA. Current prospects for interferon‐free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013;28(1):38-45
   PubMed Web of Science ®Google Scholar
• Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013;22(9):1107-21
   PubMed Web of Science ®Google Scholar
• Gentile I, Coppola N, Buonomo AR, et al. Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opin Investig Drugs 2014;23(9):1211-23
   PubMed Web of Science ®Google Scholar
• Gentile I, Buonomo AR, Zappulo E, Borgia G. Interferon-free therapies for chronic hepatitis C: Toward a hepatitis C virus-free world? Expert Rev Anti Infect Ther 2014;12(7):763-73
   PubMed Web of Science ®Google Scholar
• Lange CM, Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J Hepatol 2013;58(3):583-92
   PubMed Web of Science ®Google Scholar
• Flisiak R, Jaroszewicz J, Parfieniuk-Kowerda A. Emerging treatments for hepatitis C. Expert Opin Emerg Drugs 2013;18(4):461-75
   PubMed Web of Science ®Google Scholar
• Viekira-pak viekira-pak - viekirapak_pi.pdf. 2015. Available from: http://www.rxabbvie.com/pdf/viekirapak_pi.pdf [Accessed 22 February 2015]
   Google Scholar
• ProductFactsheet_ViekiraPak_US.pdf. 2015. Available from: http://www.abbvie.com/content/dam/abbviecorp/us/desktop/contentrooms/downloads/ProductFactsheet_ViekiraPak_US.pdf [Accessed 22 February 2015]
   Google Scholar
• Menon R, Klein C, Lawal A, et al. Pharmacokinetics and tolerability of the HCV protease inhibitor ABT-450 following single ascending doses in healthy adult volunteers with and without ritonavir. Glob Antivir J 2009;5:31-1
   Google Scholar
• Bernstein B, Menon R, Klein C, et al. Pharmacokinetics, safety and tolerability of the HCV protease inhibitor ABT-450 with ritonavir following multiple ascending doses in healthy adult volunteers. HepDART Kohala Coast; Hawaii: 2009
   Google Scholar
• Lawitz E, Gaultier I, Poordad F, et al. 4-week virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450/r) in combination with pegylated interferon alpha-2a and ribavirin (SOC) after 3-day monotherapy in genotype 1 (GT1) HCV-infected treatment-naive subjects. 2010;52(4):878A-9A
   Google Scholar
• Lawitz E, Gaultier I, Poordad F, et al. Initial antiviral activity of the HCV NS3 protease inhibitor ABT-450 when given with low dose ritonavir as 3-day monotherapy: preliminary results of study M11-602 IN genotype-1 (GT1) HCV-infected treatment-NAiVE subjects. 2010;52(4):1202A-A
   Google Scholar
• Gentile I, Borgia F, Riccardo Buonomo A, et al. ABT-450: a novel protease inhibitor for the treatment of hepatitis C virus infection. Curr Med Chem 2014;21(28):3261-70
   PubMed Web of Science ®Google Scholar
• Asselah T. ABT-450 combined with ritonavir, in addition to ABT-333 and ribavirin: a race for an interferon-free regimen to cure HCV infection. J Hepatol 2013;59(4):885-8
   PubMedGoogle Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r–ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med 2014;370(21):1983-92
   PubMed Web of Science ®Google Scholar
• Poordad F, Hezode C, Trinh R, et al. ABT-450/r–Ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014;370(21):1973-82
   PubMed Web of Science ®Google Scholar
• Clark VC, Peter JA, Nelson DR. New therapeutic strategies in HCV: second-generation protease inhibitors. Liver Int 2013;33(s1):80-4
   PubMedGoogle Scholar
• DeGoey DA, Randolph JT, Liu D, et al. Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A. J Med Chem 2014;57(5):2047-57
   PubMedGoogle Scholar
• Gentile I, Buonomo AR, Borgia G. Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection. Expert Rev Anti Infect Ther 2014;12(9):1033-43
   PubMed Web of Science ®Google Scholar
• Lok AS. New all-oral HCV therapies for genotype 1: a final good‐bye to interferon. Clinical Liver Disease 2014;3(6):137-40
   Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1594-603
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Jacobson IM, Baykal T, et al. Retreatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med 2014;370(17):1604-14
   PubMed Web of Science ®Google Scholar
• Martel-Laferriere V. ABT-450/r-ombitasvir and dasabuvir with ribavirin eliminates viraemia in most patients with HCV infection with cirrhosis. Evid Based Med 2015;20(1):6
   PubMedGoogle Scholar
• Gentile I, Buonomo AR, Borgia G. Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection. Rev Recent Clin Trials 2014;9(2):115-23
   PubMedGoogle Scholar
• Ombitasvir-paritaprevir-ritonavir and dasabuvir (viekira pak). Hepatitis C Online Web site. Available from: http://www.hepatitisc.uw.edu/pdf/page/treatment/drugs/3d Published Dec 29, 2014. Updated 2014 [Accessed 16 January 2015]
   Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014;370(3):222-32
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Lawitz E, Poordad F, et al. Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1. N Engl J Med 2014.370(3):222-32. Available from: http://dx.doi.org/10.1056/NEJMoa1306227
   Google Scholar
• Poordad F, Lawitz E, Kowdley KV, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368(1):45-53
   PubMed Web of Science ®Google Scholar
• Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology 2014;147(2):359-65. e1
   PubMed Web of Science ®Google Scholar